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Supplementary figure legends 
Supplementary Fig. 1. Immunological synapse formation protects murine DCs from 
apoptosis. (a) CFSE labelled CD4 OTII T cells were conjugated with OVA peptide-
pulsed DCs labelled with SNARF1 (OVA-DC) and then allowed to form IS with T cells 
in complete medium for 2h (see Methods). Subsequently, the cells were transferred to 
0.1% BSA in RPMI for additional 12 h. The cells were then plated onto PLL-coated 
dishes, stained with Hoechst to label the nuclei, and finally analysed under the 
immunofluorescent microscope. DCs forming IS were compared to unengaged DCs in 
the same fields. A representative immunofluorescent field is shown. Upper and lower, 
circles and squares indicate single DCs and DCs forming IS, respectively. Upper, 
Hoechst-staining of the cells shown in the lower image. White and red rectangles 
indicate DCs forming IS that are alive and apoptotic, respectively. White and red 
arrowheads indicate single DCs that are alive and apoptotic, respectively. Lower. Merge 
of Nomarski and immunofluoresce images of the cells presented in upper image. 
SNARF1-labelled DCs (red) and CFSE-labelled OTII CD4 T cells (green) are shown. 
Experiment is representative of 4 performed. (b) Percentage of OVA peptide-loaded 
DCs alone (OVA-DC) or forming IS with CD4 OTII T cells (OVA-DC+CD4) that 
present apoptotic nuclei according to Hoechst staining. An experiment representative 
out of 4 performed is shown (At least 100 single DCs and DCs forming IS were 
analysed in each experiment). 
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Supplementary Fig. 2. OVA peptide-pulsed DCs induce activation and proliferation of 
OTII T cells in vitro. (a) CD4 OTII T cells were conjugated either with unloaded 
(Unpulsed DCs) or with OVA peptide-loaded DCs (OVA-DCs). After 72 h, CD4 OTII 
T cells were stained with the anti-Vα2 TCR mAb and anti-CD69 antibodies. Numbers 
represent the percentage of T cells in the indicated quadrants (ten thousand events are 
shown). This experiment was repeated two times with similar results. CD69 staining 
profile of OTII CD4 T cells shows that T cells are activated only when they interact 
with OVA-DC. (b) CFSE-labelled CD4 OTII T cells were allowed to form conjugates 
in vitro with LPS matured splenic DCs, which were either kept unpulsed (unpulsed 
DCs) or pulsed with OVA-peptide (OVA-DCs). After 72 hours, T cell proliferation was 
determined by flow cytometry measurement of CFSE staining of CD4 T cells.  
 
Supplementary Fig. 3. Interference with immunological synapse formation induces 
apoptosis in DCs. (a) Protocol. OVA peptide-pulsed CMFDA-labelled DCs (DC) in 
complete medium (10% FCS in RPMI) were divided in two aliquots and then, for 2 h, 
kept as single DCs or mixed with SNARF-labelled OTII CD4 T cells (CD4 T cell) to 
allow IS formation. Subsequently, the cells were shifted to 0.1% BSA in RPMI for 
additional 6 h. Subsequently, single DCs and DCs forming IS (DC+CD4) were divided 
in two aliquots and then treated with 20 μg/ml of either anti-CD11a (LFA-1) blocking 
mAb (M17/4), which disrupts preformed conjugates (Ref 32), or an isotype control 
mAb. Single DCs or conjugates were left in the presence of the antibodies for additional 
12 h. The nomenclature t=6+12h indicates that the cells were first maintained in serum 
free medium (6h) and then, for additional 12 hours, in serum free medium plus the 
indicated antibodies. Finally, the cells were plated onto PLL-coated dishes, stained with 
Hoechst, and the presence of apoptotic DCs analysed under the immunofluorescence 
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microscope. (b) Percentage of apoptotic total DCs in two different experiments. In the 
samples that included DC+CD4 T cells conjugates, the total percentage of apoptotic 
DCs in each field [% apoptotic unengaged DCs + % apoptotic DCs forming IS with 
CD4 T cells] was measured (at least 200 DCs were examined in each experiment). In 
the M17/4 mAb-treated cells, reductions of 90% (Exp1) and 80% (Exp 2) in the number 
of IS were observed when compared with isotype-control-treated cells. In the DCs that 
maintained IS even in the presence of the anti-LFA-1 antibody, the IS observed had a 
reduced ability to protect the DCs from apoptosis, when compared to the IS maintained 
in the presence of the isotype control mAb (50% and 66% lower protection in Exp 1 and 
Exp 2, respectively), suggesting that blocking LFA-1 interferes with the pro-survival 
signalling emanating from the IS.  
 
Supplementary Fig. 4. Similar ability of Hoechst and FLIVO to detect apoptotic DCs 
or CD4 T cells. DCs and CD4 T cells were left for 18 h and 30 hours respectively, in 
serum-free medium and then allowed to adhere onto PLL-coated coverslips for 30 min. 
The cells were then stained with SR-FLIVO for 45 min and subsequently fixed and 
stained with Hoechst. Arrows indicate apoptotic DCs and T cells. Insets show live and 
apoptotic CD4 T cells, with similar scale magnification, doubled stained with SR-
FLIVO and Hoechst. 
 
Supplementary Fig. 5. Non-apoptotic and apoptotic DCs can be discriminated by two-
photon microscopy analysis in explanted lymph nodes. (a,b) C57/BL6 mice were 
injected in the footpads with 2x106 of OVA-pulsed CMFDA-labelled DCs (CMFDA-
DC). After 35 hours, the animals were injected intravenously with FLIVO-SR for 60 
min. Subsequently, the popliteal lymph nodes were extracted and subjected to a two-
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photon microscopy analysis. (a). Lymph node optical sections showing CMFDA-
labelled DCs (CMFDA-DC), SR-FLIVO stained DCs (SR-FLIVO) and merge images. 
(b) The profile quantification tool, provided by the Leica Confocal Software (LCS), was 
used to obtain, in the selected cells graphs with the profiles of intensities of CMFDA or 
SR-FLIVO along lineal Regions Of Interest (ROI). Maximum amplitude of the SR-
FLIVO intensity profile above and below 30, allows defining apoptotic and non-
apoptotic DCs, respectively (see Methods).  
 
Supplementary Fig. 6. Comparison of percentages of total live DCs in LNs where 
these cells can form or not IS, shows that IS formation protects the DCs from becoming 
apoptotic. (a) Experimental protocol. Preparation and injection of OVA-loaded 
CMFDA-DCs and SNARF-labelled OTII CD4 T cells is essentially as described in Fig. 
3a. Briefly, CMFDA-labelled splenic DC pulsed with OVA peptide (OVA-DCs) were 
divided in two equal aliquots that were used to inject 2 types of wild type C57/BL6 
mice, “Mice LN DC (single)” and “Mice LN DC (IS)”. While “Mice LN DC (single)” 
received only CMFDA-labelled splenic DCs (OVA-DCs), “Mice LN DC (IS)”, 18 h 
after the injection of CMFDA-labelled splenic DCs, were also i.v. injected with 
SNARF1-labeled OTII CD4 T cells to allow IS formation between these two cell types 
in the LNs. Two photon microscopy was used to determine the degree of SR-FLIVO 
staining in the CMFDA-DCs (see legend of Fig. 3 and Methods). (b) Graph shows the 
relative percentage of total live DCs (% live unengaged OVA-DCs (DCs) plus % of live 
OVA-DCs forming IS with OTII). In “Mice LN DC (IS)” the average percentage of 
DCs forming IS was 25,3±2,6 % (n=3). In the figure data are presented as the relative 
percentage of total live CMFDA-labelled OVA-DCs in the LNs. Three independent 
experiments were performed (6 LNs of “Mice LN DC (single)” and 6 LNs of “Mice LN 
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DC(IS)” were analysed and at least 100 single DCs and 80 DCs forming IS were 
analysed in the corresponding LNs). Results shown represent the mean ± s.d. *P,≤0.003 
(n=3).  
 
Supplementary Fig. 7. Immunological synapse formation induces signalling at the 
murine IS(DC). SNARF1-labelled CD4 OTII T cells (CD4, red) were allowed to form 
conjugates with unlabelled OVA peptide-pulsed DCs (OVA-DC) for 2 hours in 
complete medium (10% FCS in RPMI). Control single OVA-DCs were also maintained 
2 hours in complete medium. Subsequently, either single OVA-DCs or OVA-DC+CD4 
T cell conjugates were transferred to 0.1% BSA in RPMI for additional 2 h. At the end 
of this period, the cells were fixed, permeabilized and stained with phalloidin-FITC, to 
label F-actin, or with an anti-phospho-Tyr antibody (p-Tyr). Merge and Nοmarski 
optics are shown. (Scale bar: 5 μm). 
 
Supplementary Fig. 8. Akt1 localizes at the IS(DC). DCs transfected with either 
pEGFP-C1 vector (Vector-GFP DC) or a vector that encodes a PH domain of Akt1 
fused to GFP (PH-Akt-GFP DC) were allowed to form IS with allogeneic CD4 T cells 
for 2 h (see Fig. 4). Subsequently, the cells were transferred to 0.1% BSA in RPMI for 
additional 2 h. The cells were fixed, permeabilized, stained with Hoechst and analysed 
by confocal microscopy. Upper, GFP and Hoechst staining. Middle, GFP and Hoechst 
staining merged with Nomarski images. Bottom, staining intensity, from low intensity 
blue to high intensity red. 
 
Supplementary Fig. 9. Model indicating a mechanism whereby the IS(DC) may inhibit 
the apoptosis of DCs. Upper, in unengaged DCs, pro-survival transcription factor NF-
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κB, complexed with its inhibitor IκB, remains in the cytoplasm. In contrast, pro-
apoptotic factor FOXO1 regulates, from the nucleus, the expression of pro-apoptotic 
Bcl-2 family member Bim. Lower, upon IS formation, CD40 and other surface 
receptors (designated with an R) located at the IS(DC) induce activation of the pro-
survival kinase Akt1 and other unknown pro-survival signalling mediators (illustrated 
with an X). Akt1 activation leads to the phosphorylation, probably mediated by IκB 
kinase, of IκB, which is subsequently degraded. This allows the translocation of NF-κB 
to the nucleus, where this factor can control the transcription of pro-survival genes. 
Activated Akt1 also phosphorylates FOXO1 in the nucleus, causing its translocation to 
the cytoplasm, which inhibits the expression of Bim. Together these signals relayed 
from the IS result in the extension of the lifespan of the DCs.  
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